Why InspireMD, Inc.’s (NSPR) Stock Is Up 8.26%
As of Monday, May 11, InspireMD, Inc.’s NSPR share price has surged by 8.26%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.
Commentary & Analysis
Why InspireMD, Inc.’s (NSPR) Stock Is Down 7.69%
As of Tuesday, May 05, InspireMD, Inc.’s NSPR share price has dipped by 7.69%, which has investors questioning if this is right time to buy.Michael Rose
Why InspireMD, Inc.’s (NSPR) Stock Is Up 5.26%
As of Thursday, April 30, InspireMD, Inc.’s NSPR share price has surged by 5.26%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why InspireMD, Inc.’s (NSPR) Stock Is Up 6.12%
As of Wednesday, April 29, InspireMD, Inc.’s NSPR share price has surged by 6.12%, which has investors questioning if this is right time to sell.Michael Rose
Why InspireMD, Inc.’s (NSPR) Stock Is Down 6.25%
As of Friday, April 24, InspireMD, Inc.’s NSPR share price has dipped by 6.25%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | NSPR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $35.3 | $370.3 | 13% |
|
| Shares Out (Mil) | 84.7 | 40.8 | 59% |
|
| Institutional Ownership | 54.2% | 82.8% | 37% |
|
| Float (Mil) | 25.9 | 35.5 | 33% |
|
| Beta | 0.77 | 0.85 | 46% |
|
| Avg Daily Volume (000s) | 45 | 319 | 27% |
|
| Price Change (52-week) |
(69.0%) | 65.8% | 10% |
|
| Growth | NSPR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 29.2% | 11.8% | 89% |
|
| Net Income (5yr) | (36.0%) | (5.7%) | 11% |
|
| EPS (5yr) | 35.8% | 10.2% | 86 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.3%) | (15.5%) | 49% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.153) | ($0.453) | ($0.483) | |
| Month Ago EPS | ($0.153) | ($0.453) | ($0.483) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.187) | ($0.740) | ($0.610) | |
| Year/Year Chg | (9.5%) | (40.2%) | na | |
| Financials | NSPR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $11 | $119 | 9% |
|
| Net Income (TTM) (Mil) | ($53) | ($9) | 16% |
|
| EPS (TTM) | ($0.646) | ($0.400) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($41) | ($3) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $2 | $23 | 20% |
|
| Enterprise Value (Q1) (Mil) | $14 | $376 | 9% |
|
| Valuation | NSPR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.13 | 2.83 | 27% |
|
| P/E | na | 25.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | NSPR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 18.1% | 58.5% | 18% |
|
| Net Margin | (484.1%) | (6.9%) | 2% |
|
| ROA | (134.6%) | (12.3%) | 4% |
|
| ROE | (202.8%) | (11.1%) | 4% |
|
| Liabilities to Assets | 29.4% | 46.6% | 21% |
|
| F-Score | 3 | 4 | 18% |
|
InspireMD, Inc. did not pass any screens on 9/22/2026.
